Kerry Rogers, MD

Kerry Rogers, MD, discusses the findings observed in the phase 1b study of ianalumab in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia on ibrutinib therapy.

Kerry Rogers, MD, discusses an important unmet need in patients with hairy cell leukemia.

Kerry Rogers, MD, discusses the rationale for evaluating ibrutinib in patients with hairy cell leukemia in the phase II trial.

Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia.

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br /> &nbsp;